Genevive Hernandez-Pantua is Senior Director and Head of Clinical Biomarkers at IGM Biosciences, a biotechnology company pioneering the use of novel engineered multivalent and multispecific therapeutics. She was previously at Genentech, where she completed her postdoctoral studies on the interplay between angiogenesis and tumor immunity, and then became the Biomarker Lead for multiple trials of the breakthrough cancer immunotherapies atezolizumab (anti-PDL1 Ab) and mosunetuzumab (CD20xCD3 bispecific Ab). She obtained her PhD in Biomedical Sciences from the University of Massachusetts Medical School and BS in Molecular Biology and Biotechnology from the University of the Philippines-Diliman. She also received additional training on infectious diseases and public health at the Research Institute for Tropical Medicine in the Philippines. Dr. Hernandez-Pantua has over 20 years of experience in preclinical, translational, and clinical research encompassing vaccine development, cellular immunology, and immuno-oncology. Her passion is to develop immune-based therapies with transformative benefit.